POLD2

Across TCGA pan-cancer cohorts, POLD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POLD2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher POLD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLD2 expression acts as an unfavorable survival marker.

KIRP, MESO, and COAD are the cancer types where POLD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.270	0.904	<.001	12	view →
MESO	OS	Median	II,III,IV	0.180	0.560	.046	3	view →
COAD	OS	Median	All	0.570	0.870	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

POLD2–KIRP (OS)

Open the KIRP breakdown →